JP2022538609A5 - - Google Patents

Info

Publication number
JP2022538609A5
JP2022538609A5 JP2021577385A JP2021577385A JP2022538609A5 JP 2022538609 A5 JP2022538609 A5 JP 2022538609A5 JP 2021577385 A JP2021577385 A JP 2021577385A JP 2021577385 A JP2021577385 A JP 2021577385A JP 2022538609 A5 JP2022538609 A5 JP 2022538609A5
Authority
JP
Japan
Prior art keywords
polypeptide
cells
antigen
sequence
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021577385A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538609A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2020/051558 external-priority patent/WO2020260898A2/en
Publication of JP2022538609A publication Critical patent/JP2022538609A/ja
Publication of JP2022538609A5 publication Critical patent/JP2022538609A5/ja
Priority to JP2024197303A priority Critical patent/JP2025032114A/ja
Pending legal-status Critical Current

Links

JP2021577385A 2019-06-28 2020-06-26 新規な癌抗原及び方法 Pending JP2022538609A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024197303A JP2025032114A (ja) 2019-06-28 2024-11-12 新規な癌抗原及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19183396.1 2019-06-28
EP19183396 2019-06-28
PCT/GB2020/051558 WO2020260898A2 (en) 2019-06-28 2020-06-26 Novel cancer antigens and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024197303A Division JP2025032114A (ja) 2019-06-28 2024-11-12 新規な癌抗原及び方法

Publications (2)

Publication Number Publication Date
JP2022538609A JP2022538609A (ja) 2022-09-05
JP2022538609A5 true JP2022538609A5 (cg-RX-API-DMAC7.html) 2023-07-18

Family

ID=67145533

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021577385A Pending JP2022538609A (ja) 2019-06-28 2020-06-26 新規な癌抗原及び方法
JP2024197303A Pending JP2025032114A (ja) 2019-06-28 2024-11-12 新規な癌抗原及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024197303A Pending JP2025032114A (ja) 2019-06-28 2024-11-12 新規な癌抗原及び方法

Country Status (11)

Country Link
US (1) US20220218807A1 (cg-RX-API-DMAC7.html)
EP (1) EP3990007A2 (cg-RX-API-DMAC7.html)
JP (2) JP2022538609A (cg-RX-API-DMAC7.html)
KR (1) KR20220029560A (cg-RX-API-DMAC7.html)
CN (2) CN119119228A (cg-RX-API-DMAC7.html)
AU (1) AU2020307943A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021026375A2 (cg-RX-API-DMAC7.html)
CA (1) CA3141229A1 (cg-RX-API-DMAC7.html)
IL (1) IL289205A (cg-RX-API-DMAC7.html)
MX (1) MX2021015766A (cg-RX-API-DMAC7.html)
WO (1) WO2020260898A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119978090A (zh) 2018-10-19 2025-05-13 弗朗西斯·克里克研究所有限公司 新的癌抗原和方法
CN118666956A (zh) * 2019-06-25 2024-09-20 蒙特利尔大学 肿瘤抗原肽、肽组合、核酸、负载体、疫苗及其用途
EP3994156A1 (en) 2019-07-05 2022-05-11 The Francis Crick Institute Limited Novel cancer antigens and methods
EP4329795A1 (en) 2021-04-28 2024-03-06 Enara Bio Limited Novel cancer antigens and methods
AU2024404814A1 (en) 2023-12-19 2026-07-02 Enara Bio Limited Novel cancer antigens and methods
WO2025202937A1 (en) 2024-03-26 2025-10-02 BioNTech SE Cancer vaccines
WO2025224446A1 (en) 2024-04-23 2025-10-30 Enara Bio Limited Novel cancer antigens and methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0871747A1 (en) 1996-01-02 1998-10-21 Chiron Viagene, Inc. Immunostimulation mediated by gene-modified dendritic cells
US6488931B1 (en) * 1998-12-17 2002-12-03 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
CA2414926A1 (en) * 2000-07-07 2002-01-17 Corixa Corporation Microspheres and adjuvants for dna vaccine delivery
JPWO2004028561A1 (ja) * 2002-09-30 2006-01-19 アステラス製薬株式会社 免疫応答誘導方法
EP2402447A1 (en) 2005-03-30 2012-01-04 Viroxis Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
WO2007109583A2 (en) 2006-03-17 2007-09-27 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for prevention or treatment of neoplastic disease in a mammalian subject
US20090297530A1 (en) * 2006-05-22 2009-12-03 Feng Wang-Johanning Herv-k antigens, antibodies, and methods
US20080019979A1 (en) 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods
WO2010017330A1 (en) * 2008-08-06 2010-02-11 Novartis Ag Microparticles for use in immunogenic compositions
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
GB201102090D0 (en) * 2011-02-08 2011-03-23 Univ Sheffield Antigenic polypeptide
EP2771349B1 (en) * 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
WO2014004385A2 (en) * 2012-06-25 2014-01-03 Board Of Regents, The University Of Texas System Anti-cancer vaccines
US11319360B2 (en) * 2016-12-29 2022-05-03 Korea Institute Of Science And Technology Exosome-based anticancer agent
KR101964124B1 (ko) * 2017-03-28 2019-04-01 한국과학기술연구원 히알유로니데이즈 포함 신규 재조합 엑소좀 및 그의 용도
KR101869518B1 (ko) * 2018-03-28 2018-06-20 황인후 췌장암 줄기세포의 emt-met 가소성을 이용한 암 치료용 수지상 세포 백신의 제조 방법
CN118666956A (zh) * 2019-06-25 2024-09-20 蒙特利尔大学 肿瘤抗原肽、肽组合、核酸、负载体、疫苗及其用途

Similar Documents

Publication Publication Date Title
Salgaller et al. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides
Kawashima et al. Identification of GP100‐derived, melanoma‐specific cytotoxic T‐lymphocyte epitopes restricted by HLA‐A3 supertype molecules by primary in vitro immunization with peptide‐pulsed dendritic cells
JP2014521657A (ja) 膵臓がんに対する樹状細胞(dc)ワクチン療法
JP2022539585A5 (cg-RX-API-DMAC7.html)
JP2022540396A5 (cg-RX-API-DMAC7.html)
JP2022514116A5 (cg-RX-API-DMAC7.html)
CN114341169B (zh) 新的癌抗原和方法
CN112867501B (zh) 新的癌抗原和方法
JP2022539157A5 (cg-RX-API-DMAC7.html)
CN106243213B (zh) 一种肿瘤相关抗原XAGE-1b短肽及应用
CN119119228A (zh) 新的癌抗原和方法
CN109970846A (zh) 一种肿瘤相关抗原XAGE-1b九肽及其应用
CN106279392B (zh) 肿瘤相关抗原XAGE-1b短肽及其应用
Llopiz et al. Inhibition of adjuvant-induced TAM receptors potentiates cancer vaccine immunogenicity and therapeutic efficacy
JP2011506497A5 (cg-RX-API-DMAC7.html)
Smith et al. Immunotherapy of melanoma
CN104837497B (zh) 用于预防和治疗HPV-相关的肿瘤和其它表达p16的肿瘤的p16INK4a衍生肽
JP2022501046A (ja) アルギナーゼ1ポリペプチド
Sennikov et al. Induction of an antitumor response using dendritic cells transfected with DNA constructs encoding the HLA-A* 02: 01-restricted epitopes of tumor-associated antigens in culture of mononuclear cells of breast cancer patients
CN104341530A (zh) Vnsak多肽及其应用
EP4136096A1 (en) Antigen pool
CN105163754A (zh) 前列腺特异性肿瘤抗原及其用途
Nazarkina et al. Design of polyepitope DNA vaccine against breast carcinoma cells and analysis of its expression in dendritic cells
EP2573105B1 (en) p16INK4a derived peptides for prophylaxis and therapy of HPV-associated tumors and other p16INK4a expressing tumors
JP5946759B2 (ja) HPV関連腫瘍及び他のp16INK4a発現腫瘍の予防法及び治療法のためのp16INK4a由来ペプチド